Literature DB >> 15253698

Apoptosis in ischemic renal injury: roles of GTP depletion and p53.

Pierre C Dagher1.   

Abstract

Apoptosis is increasingly recognized as a major mode of cell demise after ischemic injury to the kidney. The mediators of apoptotic cell death are many and include changes in intracellular pH, calcium, free radicals, ceramide, and adenosine triphosphate (ATP) depletion. Recently, we identified guanosine triphosphate (GTP) depletion as an independent trigger for apoptotic death after chemical anoxia in vitro. We further demonstrated that GTP salvage with guanosine inhibits tubular cell apoptosis after ischemic injury in vivo. This inhibition of apoptosis was accompanied by a significant protective effect on renal function. We also showed that p53 is the mediator of apoptosis in the setting of GTP depletion and ischemic injury. Indeed, salvage of GTP with guanosine prevented the ischemia-induced increase in p53 protein. Further, pifithrin-alpha, a potent and specific inhibitor of p53, inhibited apoptosis and protected renal function with a profile similar to that seen with guanosine. Finally, the protective effects of pifithrin-alpha involved both down-regulation of the transcriptional activation of Bax and a direct inhibition of p53 translocation to mitochondria. We propose that GTP depletion and activation of p53 are major inducers of apoptotic cell death after ischemic renal injury. In this setting, guanosine and pifithrin-alpha are potent inhibitors of apoptosis and are thus potentially useful in preventing and ameliorating functional injury to the ischemic kidney.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15253698     DOI: 10.1111/j.1523-1755.2004.761_7.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  29 in total

1.  Monoubiquitylation promotes mitochondrial p53 translocation.

Authors:  Natasha D Marchenko; Sonja Wolff; Susan Erster; Kerstin Becker; Ute M Moll
Journal:  EMBO J       Date:  2007-02-01       Impact factor: 11.598

2.  p53 target Siva regulates apoptosis in ischemic kidneys.

Authors:  Kurinji Singaravelu; Babu J Padanilam
Journal:  Am J Physiol Renal Physiol       Date:  2011-02-09

Review 3.  Pathologies associated with the p53 response.

Authors:  Andrei V Gudkov; Elena A Komarova
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-07       Impact factor: 10.005

4.  Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models.

Authors:  Florian E Tögel; Jon D Ahlstrom; Ying Yang; Zhuma Hu; Ping Zhang; Christof Westenfelder
Journal:  J Am Soc Nephrol       Date:  2016-03-16       Impact factor: 10.121

5.  JAK2/Y343/STAT5 signaling axis is required for erythropoietin-mediated protection against ischemic injury in primary renal tubular epithelial cells.

Authors:  A C Breggia; D M Wojchowski; J Himmelfarb
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

6.  Comparison of renal damage by iodinated contrast or gadolinium in an acute renal failure rat model based on serum creatinine levels and apoptosis degree.

Authors:  Hyo-Sung Kwak; Young-Hwan Lee; Young-Min Han; Gong-Yong Jin; Won Kim; Gyung-Ho Chung
Journal:  J Korean Med Sci       Date:  2005-10       Impact factor: 2.153

7.  Netrin-1 overexpression protects kidney from ischemia reperfusion injury by suppressing apoptosis.

Authors:  Weiwei Wang; William Brian Reeves; Laurent Pays; Patrick Mehlen; Ganesan Ramesh
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

Review 8.  Proteomics for biomarker discovery in acute kidney injury.

Authors:  Prasad Devarajan
Journal:  Semin Nephrol       Date:  2007-11       Impact factor: 5.299

Review 9.  p53 and metabolism.

Authors:  Karen H Vousden; Kevin M Ryan
Journal:  Nat Rev Cancer       Date:  2009-09-17       Impact factor: 60.716

10.  Primary mouse renal tubular epithelial cells have variable injury tolerance to ischemic and chemical mediators of oxidative stress.

Authors:  Anne C Breggia; Jonathan Himmelfarb
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.